Figure 1.

Screening for antiglycine receptor (GlyR) antibodies was performed using a cell-based-assay. Patient cerebrospinal fluid (CSF) (1:20 dilution) was applied on live human embryonic kidney 293T cells, transiently transfected with full-length GlyR enhanced green fluorescent protein (EGFP), followed by a goat-anti-human secondary antibody (AlexaFluor-568). (a) CSF obtained at 10 days in the intensive care unit (ICU). (b) CSF obtained at 63 days in the ICU (c) CSF obtained at 75 days in the ICU. Falling titers of anti-GlyR antibodies can be observed.

Scale bar 100μm.